-
Saudi Journal of Ophthalmology :... 2015The term intermediate uveitis (IU) refers to a subgroup of uveitis in which the vitreous is the site of greatest inflammation. Patients with multiple sclerosis (MS) have...
The term intermediate uveitis (IU) refers to a subgroup of uveitis in which the vitreous is the site of greatest inflammation. Patients with multiple sclerosis (MS) have a greater frequency of IU compared with the general population. The IU associated with MS is characterized by the presence of pars planitis (occasionally accompanied by anterior uveitis) and the presence of peripheral retinal vasculitis in the form of periphlebitis (venous sheathing) in 6-26% of patients. We present a patient with an unusual initial presentation of MS involving central retinal artery occlusion (CRAO) in the right eye (RE). Although retinal vascular changes are asymptomatic in the majority of MS patients, the spectrum of impairment ranges from simple peripheral retina periphlebitis to the presence of peripheral occlusive retinal vasculitis in 6.5% of patients. This atypical case may represent an extreme of the spectrum of retinal vasculitis associated with demyelinating disease.
PubMed: 25892937
DOI: 10.1016/j.sjopt.2014.12.001 -
Arquivos Brasileiros de Oftalmologia 2015To evaluate the use of a slow-release dexamethasone 0.7-mg intravitreal implant for cystoid macular edema (CME) secondary to intermediate uveitis and refractory to...
PURPOSE
To evaluate the use of a slow-release dexamethasone 0.7-mg intravitreal implant for cystoid macular edema (CME) secondary to intermediate uveitis and refractory to systemic steroids.
METHODS
A retrospective study of the best-corrected visual acuity (BCVA), intraocular inflammation, intraocular pressure (IOP), fundus photography, optical coherence tomography (OCT), inflammation, and adverse reactions of five patients (women, mean age of 35 years) with cystoid macular edema treated with a dexamethasone implant. Patients were evaluated in seven visits until the 150th day after the implant.
RESULTS
Four patients had bilateral pars planitis and one had bilateral intermediate uveitis associated with juvenile idiopathic arthritis. Six dexamethasone devices were implanted, under topical anesthesia (one each in six eyes, five patients). The mean follow-up time was 5 months. The best-corrected visual acuity improved in all eyes that received an implant, with five having improvements of two or more lines. Optical coherence tomography showed thinning of the macula in all eyes treated, and we saw a correlation between the best-corrected visual acuity and retinal thinning. No serious adverse events occurred and no significant increase in intraocular pressure was observed.
CONCLUSIONS
Slow-release dexamethasone intravitreal implants can effectively treat CME secondary to intermediate uveitis and refractory to systemic steroids.
Topics: Adult; Aged; Anti-Inflammatory Agents; Delayed-Action Preparations; Dexamethasone; Drug Implants; Female; Humans; Macular Edema; Middle Aged; Retrospective Studies; Uveitis, Intermediate; Visual Acuity; Young Adult
PubMed: 26222112
DOI: 10.5935/0004-2749.20150049 -
BMJ Case Reports Sep 2018
Topics: Child; Coloboma; Humans; Iris; Male; Pars Planitis; Retinal Detachment; Retinal Perforations; Tomography, Optical Coherence; Treatment Outcome; Vision Disorders; Visual Acuity; Vitrectomy
PubMed: 30173139
DOI: 10.1136/bcr-2018-226919